IBDEI0I5 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8787,0)
 ;;=362.51^^52^586^1
 ;;^UTILITY(U,$J,358.3,8787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8787,1,3,0)
 ;;=3^AMD,Dry
 ;;^UTILITY(U,$J,358.3,8787,1,4,0)
 ;;=4^362.51
 ;;^UTILITY(U,$J,358.3,8787,2)
 ;;=^268636
 ;;^UTILITY(U,$J,358.3,8788,0)
 ;;=362.52^^52^586^2
 ;;^UTILITY(U,$J,358.3,8788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8788,1,3,0)
 ;;=3^AMD,Wet/Exudative
 ;;^UTILITY(U,$J,358.3,8788,1,4,0)
 ;;=4^362.52
 ;;^UTILITY(U,$J,358.3,8788,2)
 ;;=^268637
 ;;^UTILITY(U,$J,358.3,8789,0)
 ;;=362.04^^52^586^14
 ;;^UTILITY(U,$J,358.3,8789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8789,1,3,0)
 ;;=3^DM Mild NPDR
 ;;^UTILITY(U,$J,358.3,8789,1,4,0)
 ;;=4^362.04
 ;;^UTILITY(U,$J,358.3,8789,2)
 ;;=^332787
 ;;^UTILITY(U,$J,358.3,8790,0)
 ;;=362.05^^52^586^15
 ;;^UTILITY(U,$J,358.3,8790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8790,1,3,0)
 ;;=3^DM Moderate NPDR
 ;;^UTILITY(U,$J,358.3,8790,1,4,0)
 ;;=4^362.05
 ;;^UTILITY(U,$J,358.3,8790,2)
 ;;=^332788
 ;;^UTILITY(U,$J,358.3,8791,0)
 ;;=362.06^^52^586^17
 ;;^UTILITY(U,$J,358.3,8791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8791,1,3,0)
 ;;=3^DM Severe NPDR
 ;;^UTILITY(U,$J,358.3,8791,1,4,0)
 ;;=4^362.06
 ;;^UTILITY(U,$J,358.3,8791,2)
 ;;=^332789
 ;;^UTILITY(U,$J,358.3,8792,0)
 ;;=362.02^^52^586^16
 ;;^UTILITY(U,$J,358.3,8792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8792,1,3,0)
 ;;=3^DM PDR
 ;;^UTILITY(U,$J,358.3,8792,1,4,0)
 ;;=4^362.02
 ;;^UTILITY(U,$J,358.3,8792,2)
 ;;=^268610
 ;;^UTILITY(U,$J,358.3,8793,0)
 ;;=367.9^^52^586^18
 ;;^UTILITY(U,$J,358.3,8793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8793,1,3,0)
 ;;=3^Disorder of Refraction
 ;;^UTILITY(U,$J,358.3,8793,1,4,0)
 ;;=4^367.9
 ;;^UTILITY(U,$J,358.3,8793,2)
 ;;=^35634
 ;;^UTILITY(U,$J,358.3,8794,0)
 ;;=373.2^^52^586^36
 ;;^UTILITY(U,$J,358.3,8794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8794,1,3,0)
 ;;=3^Meibomianitis
 ;;^UTILITY(U,$J,358.3,8794,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,8794,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,8795,0)
 ;;=V58.69^^52^586^34
 ;;^UTILITY(U,$J,358.3,8795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8795,1,3,0)
 ;;=3^Long Term Use of Medication
 ;;^UTILITY(U,$J,358.3,8795,1,4,0)
 ;;=4^V58.69
 ;;^UTILITY(U,$J,358.3,8795,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,8796,0)
 ;;=379.24^^52^586^51
 ;;^UTILITY(U,$J,358.3,8796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8796,1,3,0)
 ;;=3^Vitreous Floaters
 ;;^UTILITY(U,$J,358.3,8796,1,4,0)
 ;;=4^379.24
 ;;^UTILITY(U,$J,358.3,8796,2)
 ;;=^88242
 ;;^UTILITY(U,$J,358.3,8797,0)
 ;;=V80.2^^52^586^47
 ;;^UTILITY(U,$J,358.3,8797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8797,1,3,0)
 ;;=3^Screening for Eye Condition
 ;;^UTILITY(U,$J,358.3,8797,1,4,0)
 ;;=4^V80.2
 ;;^UTILITY(U,$J,358.3,8797,2)
 ;;=^295685
 ;;^UTILITY(U,$J,358.3,8798,0)
 ;;=V70.5^^52^586^48
 ;;^UTILITY(U,$J,358.3,8798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8798,1,3,0)
 ;;=3^Screening,Occupational
 ;;^UTILITY(U,$J,358.3,8798,1,4,0)
 ;;=4^V70.5
 ;;^UTILITY(U,$J,358.3,8798,2)
 ;;=^295595
 ;;^UTILITY(U,$J,358.3,8799,0)
 ;;=365.11^^52^586^27
 ;;^UTILITY(U,$J,358.3,8799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8799,1,3,0)
 ;;=3^Glaucoma Primary Open Angle
 ;;^UTILITY(U,$J,358.3,8799,1,4,0)
 ;;=4^365.11
 ;;^UTILITY(U,$J,358.3,8799,2)
 ;;=^51203
 ;;^UTILITY(U,$J,358.3,8800,0)
 ;;=365.70^^52^586^29
 ;;^UTILITY(U,$J,358.3,8800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8800,1,3,0)
 ;;=3^Glaucoma Stage NOS
 ;;^UTILITY(U,$J,358.3,8800,1,4,0)
 ;;=4^365.70
 ;;^UTILITY(U,$J,358.3,8800,2)
 ;;=^340609
 ;;^UTILITY(U,$J,358.3,8801,0)
 ;;=365.74^^52^586^23
